Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA:600420)

Market Cap	14.42B
Revenue (ttm)	10.42B
Net Income (ttm)	1.11B
Shares Out	1.34B
EPS (ttm)	0.83
PE Ratio	12.94
Forward PE	10.76
Dividend	0.30 (2.79%)
Ex-Dividend Date	Sep 20, 2024

Volume	6,660,396
Average Volume	12,214,199
Open	10.77
Previous Close	10.75
Day's Range	10.70 - 10.82
52-Week Range	9.69 - 14.41
Beta	0.37
RSI	59.08
Earnings Date	Aug 28, 2025

About SHA:600420

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, 7-ADCA, 7-ACA, D-7ACA, and penicillin industrial potassium; pharmaceutical intermediates, anti-infective pharmaceutical intermediates salt, and ceftriaxone sodium crude salt; and amoxicillin, clavulanic acid series, azithromycin, and ceftriaxone sodium. It also provides anti-infective pharmaceutical raw materials; urogenital system pharmaceutical raw materials, systemic anti-infec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 11,472
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600420

Financial Performance

In 2024, SHA:600420's revenue was 10.94 billion, a decrease of -9.38% compared to the previous year's 12.07 billion. Earnings were 1.08 billion, an increase of 56.62%.